title: [A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel].
abstract: We report a case of a 58-year-old man with advanced gastric cancer producing sialyl-Tn antigen (STN). Total gastrectomy with distal pancreatectomy and splenectomy was performed. Pathological staging was IV (T 3 N 2 CY1), and most of the cancer cells were strongly positive for anti-STN antibody on immunohistochemical stainings. Serum STN level before the operation was 2,500 U/ml, and the value significantly decreased to the normal range (< 45 U/ml) 2 months after the operation. Low-dose FP (5-FU+CDDP) followed by TS-1 alone (80 mg/day) had been performed as adjuvant chemotherapy. Jaundice appeared and the serum STN level increased again 22 months after the operation. He was diagnosed with a recurrence in the hilar lymph node of the liver. After implantation of expandable stent in the common bile duct, triweekly docetaxel therapy with TS-1 administration (day 1-14) has been performed. Three courses of this therapy have induced a complete response of the recurrent lymph node and the normalization of the serum STN value. No major adverse reaction to this therapy was observed. A complete response and good patient QOL have been achieved during follow-up 8 months after the administration of TS-1 with docetaxel. This case suggests that patients with recurrent gastric cancer who have undergone prior therapy with TS-1 alone could benefit from TS-1 with docetaxel therapy as a second line.
authors.affiliation: Dept of Surgery, Nissay Hospital, Nippon Life Saiseikai Foundation.
authors.forename: Masaya
authors.initials: M
authors.lastname: Nomura
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Inoue
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Katsura
authors.forename: Shigeo
authors.initials: S
authors.lastname: Fujita
authors.forename: Jun
authors.initials: J
authors.lastname: Sakao
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Yokotani
authors.forename: Shigeo
authors.initials: S
authors.lastname: Souda
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005743:Gastrectomy; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid / Q000008:administration & dosage / Q000494:pharmacology; D010180:Pancreatectomy; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology; D013156:Splenectomy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D004338:Drug Combinations; D011725:Pyridines; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid